TPH2
Tryptophan 5-hydroxylase 2
As of the edition of 20 October 2026, TPH2 (tryptophan 5-hydroxylase 2, UniProt Q8IWU9) has 2 drugs tested at it and 3 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q8IWU9
- How well studied
- Chemical tools exist; no approved drug acts on it
- Solved structures
- 5
- Disease areas
- Chemically induced; Cancer; Digestive system; Hormones; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 27
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Telotristat ethyl | Marketed | Phase 3 | Ends 2031 |
| Telotristat | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| TerSera Therapeutics | Route B |
| Serb | Route B |
The other 1 company at TPH2
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at TPH2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.